Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

NCT03360682 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection
Solid Organ Transplant

Interventions

DRUG: Lamivudine 300 MG
DRUG: Abacavir 600 MG
DRUG: Dolutegravir 50 mg
DRUG: Tenofovir Disoproxil 245Mg Tablet
DRUG: Emtricitabine 200 MG

Sponsor

Fundacion Clinic per a la Recerca Biomédica